Sanofi (SNY)
| Market Cap | 106.43B -19.5% |
| Revenue (ttm) | 54.60B +4.8% |
| Net Income | 8.71B +19.9% |
| EPS | 3.58 +23.0% |
| Shares Out | 1.20B |
| PE Ratio | 12.22 |
| Forward PE | 8.90 |
| Dividend | $1.76 (3.99%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 1,559,053 |
| Open | 44.11 |
| Previous Close | 44.11 |
| Day's Range | 44.02 - 44.51 |
| 52-Week Range | 42.28 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 55.90 (+26.33%) |
| Earnings Date | Jul 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $55.9, which is an increase of 26.33% from the latest price.
News
Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes
Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes
FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes
(RTTNews) - Sanofi (SNY) announced that the U.S. Food and Drug Administration has granted accelerated approval to Tzield (teplizumab-mzwv) for delaying the decline in endogenous insulin production in ...
Sanofi: Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerated approval in children aged eight to 17 years old re...
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
The U.S. Food and Drug Administration approved Sanofi's injection to slow the loss of the body's own insulin production in children aged 8 to 17 years recently diagnosed with stage 3 typ...
Strong Buy Rating on Sanofi (SNY) Following Positive Study Results
Strong Buy Rating on Sanofi (SNY) Following Positive Study Results
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move ...
Sanofi (SNY) Halts Study, Analyst Says Dianthus Selloff Overstated
Sanofi (SNY) Halts Study, Analyst Says Dianthus Selloff Overstated
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright
After Sanofi (SNY) announced that it is stopping the pivotal MOBILIZE study evaluating riliprubart in chronic inflammatory demyelinating polyneuropathy patients refractory to standard of care based on...
Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics
Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics
Dianthus Therapeutics (DNTH) Shares Drop Over 20% Following Sanofi Trial Halt
Dianthus Therapeutics (DNTH) Shares Drop Over 20% Following Sanofi Trial Halt
Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
Stifel notes that Sanofi (SNY) announced this morning that they are discontinuing the MOBILIZE Phase 3 study of riliprubart in CIDP patients refractory to IVIg based on an IDMC interim…
Dianthus sinks after Sanofi halts CIDP Phase 3 study
Shares of Dianthus Therapeutics (DNTH) after sinking after Sanofi (SNY) announced that its riliprubart Phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy will be stopped....
Sanofi (SNY) Halts Phase 3 Study on CIDP Treatment
Sanofi (SNY) Halts Phase 3 Study on CIDP Treatment
Sanofi to halt riliprubart Mobilize phase 3 study
Sanofi (SNY) announced that the riliprubart Mobilize phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy, CIDP, refractory to standard-of-care treatment will be stopped. T...
Sanofi (SNY) Halts Phase 3 Trial of Riliprubart Due to Efficacy Concerns
Sanofi (SNY) Halts Phase 3 Trial of Riliprubart Due to Efficacy Concerns
Sanofi Discontinues Phase 3 MOBILIZE Trial For Riliprubart In Treating CIDP
(RTTNews) - Sanofi (SNY), a biopharmaceutical company, on Wednesday announced the discontinuation of the Phase 3 MOBILIZE trial for Riliprubart in treating chronic inflammatory demyelinating polyneuro...
Sanofi ends Phase 3 riliprubart trial after weak interim results
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient...
Sanofi to Stop Late-Stage Study of Immune-Disorder Drug
The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.
Sanofi: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today announced that the riliprubart MOBILIZE phase...
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026 . Sanofi today announced that the riliprubart MOBILIZE phase ...
Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics...
Sanofi: EC Approves Sarclisa SC For Multiple Myeloma, First EU Therapy Via On-Body Injector
(RTTNews) - The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across a...
Sanofi: Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sarclisa administered via the CirCLIQ OBI offers a treatment experience desi...
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaborat...